Structure de mise en forme 2 colonnes

Integrated MicroNano-Opto Fluidic systems for high-content-diagnosis and studies of rare cancer cells. 

31 December 2012 : End of the project

See the results on the final brochure and on cordis news



The CAMINEMS project is supported by the European Commission and aims at developing new tools based on microfluidics and nanotechnologies, to improve cancer diagnosis and prognosis.

Cancer causes about 13% of all deaths in the world and thus represents a huge problem in public health. In particular, today, about 90% of cancer deaths are due to metastases and therapeutic escape.

At the origin of metastases are Circulating Tumour Cells (CTC), individual cells or small cellular issued from the primary cancer and transiently circulated in the blood. It would be a major breakthrough for treatments to be able to perform a detailed molecular characterisation on CTC before they develop into metastases.
Besides this major diagnosis and prognosis application, being able to capture and to study CTC would also be a highly valuable help in research, for understanding their metabolism, and their response to existing or candidate drugs.

For all these applications, current technologies are insufficient both in sensitivity and specificity. They can detect micrometastases only in patients with advanced cancer, and they only allow the  identification of a few biomarkers. Providing a tool for overcoming these limitations, based on innovations in converging sciences, is the main objective of CAMINEMS.